# CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

> **NCT05289193** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Melanoma
- Melanoma Stage III

## Interventions

- **DIAGNOSTIC_TEST:** PET Scan
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **PROCEDURE:** Surgical Resection of Melanoma

## Key facts

- **NCT ID:** NCT05289193
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-11
- **Primary completion:** 2027-03-11
- **Final completion:** 2027-03-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289193, "CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05289193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*